Barclays raised the firm’s price target on PTC Therapeutics (PTCT) to $45 from $43 and keeps an Equal Weight rating on the shares. After ...

In a report released today, Gena Wang from Barclays maintained a Hold rating on PTC Therapeutics (PTCT – Research Report), with a price target of $45.00. The company’s shares closed yesterday at ...

Key events this week, including the US CPI data and the speech by the Federal Reserve Chair, will be critical in providing ...

Brokerage Geojit has set a new target price of Rs 582 owing to surge in large deals which is expected to support the companys ...

PTC projected adjusted earnings per share of 75 cents to 95 cents for the quarter, compared with analysts' estimate of $1.33. For the fiscal year 2025, PTC expects revenue to be between $2.51 billion ...

A trader wears a hat in support of Republican Donald Trump, after he won the U.S. presidential election, at the New York ...

Panellists were announced during annual conference for The Personal Travel Consultants in Partnership with Blue Bay Travel, ...

ICON plc (NASDAQ:ICLR) traded sharply lower on Thursday, sparking a selloff among its rival contract research organizations after the Ireland-based company cut its guidance with its Q3 results. In ...

“A multitalented personality, the actress, producer and fashion icon henceforth embodies the audacity, grace and elegance of Dior style, a femininity constantly reinvented,” the press release ...

Read full article: SoDo residents raise concerns over proposed homeless shelter Read full article: ‘It’s my civic duty:’ A last look at long lines for early voting in Central Florida Wine ...

Potential bidders include rival design software makers such as PTC and Cadence Design Systems, the sources said. Reuters could not determine whether PTC and Cadence have approached Altair.

The therapy’s maker, PTC Therapeutics, is committed to keeping Translarna available in the meantime. “As Translarna will remain authorized in Europe pending review by the European Commission, we will ...